12 results about "Injection drug use" patented technology

The invention provides a sterile, injectable pharmaceutical composition which includes a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof, a nitrite scavenger, a tonicity agent, and water, wherein the composition contains less than about 300 ppb of an N-nitrosoketamine impurity. The invention also provides a pharmaceutical product which includes a container and the composition of the invention aseptically sealed therein. The invention further provides a process for preparing the composition and product of the invention.

Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.

An object of the present invention is to provide an injectable pharmaceutical composition containing difelikefalin that can reduce human errors and labor involved in dosage preparation in medical settings. [Solution] The present invention relates to an injectable pharmaceutical composition containing difelikefalin or a pharmacologically acceptable salt thereof for treating pruritus in dialysis patients, which is an injectable pharmaceutical composition that reduces human error and labor involved in dosage preparation in medical settings, and which contains difelikefalin or a pharmacologically acceptable salt thereof in an amount of 17.5 μg, 25.0 μg, 35.0 μg, or 42.5 μg, calculated as the free form of difelikefalin, and is intended to be administered to dialysis patients with a dry weight of less than 45 kg, 45 kg or more but less than 65 kg, 65 kg or more but less than 85 kg, or 85 kg or more, respectively.

The invention relates to an injectable composition comprising compound I, pharmaceutically acceptable salts or solvates thereof; and at least one pharmaceutically acceptable excipient, wherein the injectable composition provides sustained release of compound I and thereby maintains blood plasma fulvestrant concentration. Also, the present invention used for method of treatment of breast cancer comprising compound of formula I, pharmaceutically acceptable salts or solvates thereof; and at least one pharmaceutically acceptable excipient.

An injectable pharmaceutical composition comprising a solution of 3-acyl-buprenorphine or a pharmaceutical salt thereof in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a sustained release profile lasting for more than one week when injected into a patient. The acyl group is an alkylcarbonyl group and an alkyl portion of the alkylcarbonyl group is straight chain, branched chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, isopropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.

The present invention relates to improved injectable pharmaceutical compositions comprising one or more therapeutic compounds, or pharmaceutically acceptable salts thereof, that have been developed to significantly reduce both gastrointestinal adverse events (GI AEs) and any accompanying serious adverse events (SAEs) relative to the high rates of GI AEs and SAEs that presently accompany administration of existing pharmaceutical compositions (whether as oral or injectable formulations) of the same therapeutic compounds. Also provided are processes of manufacture and methods of administering the improved injectable pharmaceutical compositions to patients for the treatment of a disease or disorder, such as obesity or overweightedness.

The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.

1. The name of the design product: pharmacological pyrogen instrument. 2. The use of the design product: the design product detects the pyrogen in the injection drug by observing the body temperature change of the house rabbit. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The invention provides a sterile, injectable pharmaceutical composition which includes a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof, a nitrite scavenger, a tonicity agent, and water, wherein the composition contains less than about 300 ppb of an N-nitrosoketamine impurity. The invention also provides a pharmaceutical product which includes a container and the composition of the invention aseptically sealed therein. The invention further provides a process for preparing the composition and product of the invention.

The present invention aims to provide an injectable pharmaceutical composition containing diferikephalin that can reduce human error and labor associated with dosage preparation in medical settings. [Solution] The present invention relates to an injectable pharmaceutical composition containing diferikephalin or a pharmacoagulably acceptable salt thereof for the treatment of pruritus in dialysis patients, wherein the injectable pharmaceutical composition is designed to reduce human error and labor associated with dosage preparation in medical settings, and the injectable pharmaceutical composition contains diferikephalin or a pharmacoagulably acceptable salt thereof in amounts of 17.5 μg, 25.0 μg, 35.0 μg, or 42.5 μg in free form equivalent, and relates to an injectable pharmaceutical composition for administration to dialysis patients with a dry weight of less than 45 kg, 45 kg or more but less than 65 kg, 65 kg or more but less than 85 kg, or 85 kg or more, respectively.

The present invention relates to: a fusion protein comprising a growth hormone receptor antagonist and a long-acting carrier, the growth hormone receptor antagonist comprising a growth hormone variant in which one or more amino acids in the amino acid sequence of growth hormone are substituted with another amino acid; and a pharmaceutical composition, preferably a pharmaceutical composition for subcutaneous injection, comprising the fusion protein. A pharmaceutical composition comprising a growth hormone receptor inhibitor, a carrier, and hyaluronidase, according to the present invention, may have strong binding affinity to the growth hormone receptor and may exhibit sustained antagonism. A pharmaceutical composition for subcutaneous injection, comprising a growth hormone receptor inhibitor, a carrier, and hyaluronidase, according to the present invention, may increase the amount of a drug for subcutaneous injection, thereby increasing the amount of the drug absorbed into the human body without a rapid increase in the concentration of the growth hormone receptor inhibitor.

The application belongs to the technical field of biological medicine, and discloses an injection drug liposome for treating non-small cell lung cancer, and a preparation method and application thereof. The liposome is composed of dehydroabietyl acid derivative BPC as an active ingredient, a lipid carrier composed of phospholipid and cholesterol, and pharmaceutically acceptable injection adjuvants. The liposome is prepared by optimizing the prescription ratio and adopting a film dispersion-high pressure homogenization method. The application solves the technical problems of poor water solubility of BPC, inability to inject drug delivery, and low bioavailability. The obtained liposome has uniform particle size, high encapsulation efficiency and drug loading capacity, excellent sustained release effect and storage stability. In-vivo and in-vitro tests prove that the liposome has significant targeted anti-tumor activity on non-small cell lung cancer, can greatly reduce drug toxicity and side effects, has good safety, and has a simple and controllable preparation process, is suitable for industrial production, and has excellent clinical application value.